Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed, replacing the previous v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T00:54:55.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding-status notice and Revision: v3.4.1 text.
    Difference
    0.4%
    Check dated 2026-02-11T14:33:08.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about a funding lapse and NIH Clinical Center operations, and updated the page version from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:42:45.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Show glossary toggle added to the page. Minor wording/capitalization changes were made to labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and the revision tag updated to v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-28T06:24:10.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page version was updated from v3.3.3 to v3.3.4, with Revision: v3.3.4 added and Revision: v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:15:29.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Added a Locations section listing study sites in Florida, Maryland, New Jersey, Ohio, and Texas with revision v3.3.3. Removed the separate state-location entries for Florida, Maryland, New Jersey, Ohio, and Texas and the HHS Vulnerability Disclosure link.
    Difference
    0.6%
    Check dated 2025-12-23T22:50:26.000Z thumbnail image

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.